# Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4

> **NCT04387526** · PHASE2,PHASE3 · COMPLETED · sponsor: **Beni-Suef University** · enrollment: 946 (actual)

## Conditions studied

- Chronic Hepatitis C Virus Infection

## Interventions

- **DRUG:** (SOF and DCV)
- **DRUG:** (SOF, DCV, and RBV)

## Key facts

- **NCT ID:** NCT04387526
- **Lead sponsor:** Beni-Suef University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-01
- **Primary completion:** 2017-05-31
- **Final completion:** 2017-05-31
- **Target enrollment:** 946 (ACTUAL)
- **Last updated:** 2020-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04387526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04387526, "Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04387526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*